At the meeting, a wealth of new data on some of the most promising cell and gene therapies in development for oncology and other indications was presented. CAR-Ts in particular were seen to be advancing rapidly, with well over 100 products in development.
This webinar considers which countries are leading the way in financing cell and gene therapies, and how their approaches can be adopted elsewhere, as well as the implications for the clinical pipeline as the growing number of reimbursed cell and gene therapies strains national budgets.
Learnings from ASH
US experience with CAR-T reimbursement
Implications for the market access of cell and gene therapies.
Duration: 45 minutes. Available to watch on demand.
Ideal viewing: Global, regional, and affiliate market access and HEOR teams involved in pricing strategy and pricing and reimbursement decisions can benefit from watching this on-demand webinar. Please share this with your colleagues.
Market access considerations for CAR-Ts: insights from ASH
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.